# Darbepoetin alfa

## NESP inj 20mcg(洗腎用)

| TAH Drug Code      | [INESP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=INESP)                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of anemia associated with chronic renal dysfunction or requiring blood transfusion due to this condition, as well as treatment of symptomatic anemia associated with cancer chemotherapy.                                                                                                                                                                                                                                                                                                                        |
| Dosing             | Initial dose as 0.45mcg/kg IV or SC every week for treatment of chronic renal failure patient with anemia, keeping Hb between 10-12g/dL. For patient with chemotherapy, 2.25mcg/kg SC as initial dose.                                                                                                                                                                                                                                                                                                                     |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | ESAs should not be used to treat patients receiving myelosuppressive chemotherapy who are expected to be cured. ESAs should not be used to treat patients receiving myelosuppressive chemotherapy who are expected to be cured. Discontinue use after completing the chemotherapy regimen. Uncontrolled hypertension patients. Pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoiesis-stimulating agents. Patients with known severe hypersensitivity to darbepoetin alfa. |
| Adverse Effects    | Hypertension (31%), peripheral edema (17%), edema (6% to 13%), Abdominal pain (10% to 13%), Dyspnea (17%), cough (12%)                                                                                                                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | Compatible – Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/darbepoetin-alfa-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                            |

